about
Target enrichment and high-throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemia.A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCRResponses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsTechnical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibEVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia.PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization.Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia.A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPsCytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization resultsTranslocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosisMultiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosisDuplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignanciesPoor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyStandardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1Pushing the boundaries of in situ hybridisation for mRNA demonstration: demonstration of kappa and lambda light chain restriction in follicular lymphomaCorrection: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
P50
Q34746794-CD6B51BA-1F5D-4F1C-9990-2EAF134DA49EQ35059443-6D416F3C-A3F9-4CDD-AF8D-002C46B5BDA0Q37511076-73688B9C-9AB2-4E4E-B78B-5459B490DE20Q37526747-A38FB44E-8029-4DD1-975D-B40C4902A100Q37588786-ACEAC080-A31D-4D1F-ACD1-0A6FBC13C319Q37662338-A3C0DBB5-7F9C-4C7D-AC71-03079E8AF502Q37974490-12CC2020-8D01-453E-9C31-FE4F77178E4FQ39934787-1F3330EB-F5A0-4CDA-8D52-7D16465A9FD5Q40351309-5E68D0EE-885F-40C4-98DA-0D0E1A40F25DQ42069460-9FBE9C3A-DC8C-4906-A7CF-446EF68CCB4FQ42882348-8703E8E5-5F96-45CC-A17B-5FCFC5D3821CQ43072797-FE722156-1B94-4CB7-B5C2-B25E335573B8Q43979129-599ECBAE-D170-484B-8FD4-10FCB05B85C4Q44270173-03DCC58D-9F5E-41FE-A680-090C163645FBQ51555431-14BA0F9F-8AAD-4226-8EE4-85437270753EQ53017093-6DF2C4C7-11C3-4B12-A644-0B4028E4C068Q53130757-378907F7-E3E7-405B-A27E-0CDD5F1A31B3Q54212836-331B2EAD-4E89-49C3-A2ED-DD85022765CEQ54240000-441A7120-9852-4F76-AC58-4DFE1056E02CQ54397703-17463027-A95A-44DC-97B1-1A82A4145AB2Q54495485-10765273-3ADF-4BC8-B06F-035E64915636Q54551498-B7B03067-EC56-43AB-9504-4D4AB5F68EC6Q57405363-31369890-21D4-4E15-A8D4-9251BBDA9C87Q58481891-B5615088-C25F-4EE9-BE82-6406E169CF34Q58481903-7893B778-31C7-4D2A-82E5-6B03C7D6ECF3Q81721369-82253380-7CDD-4BD1-A6C6-E806B8A44CC8Q83427638-4EEE7FBF-8623-46F5-BD22-137FF247C625Q83465806-073E6FD2-69CB-4D2C-9435-56D0561E2457Q92284305-58167941-6036-4452-90DA-19CE1AF03BE1Q92497153-2DA6EE4F-CB4B-4F9D-8469-1905DAF05E79Q92643788-EC6B5BE0-FBBC-433C-A607-E562EA873241
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gareth Gerrard
@ast
Gareth Gerrard
@en
Gareth Gerrard
@es
Gareth Gerrard
@nl
Gareth Gerrard
@sl
type
label
Gareth Gerrard
@ast
Gareth Gerrard
@en
Gareth Gerrard
@es
Gareth Gerrard
@nl
Gareth Gerrard
@sl
prefLabel
Gareth Gerrard
@ast
Gareth Gerrard
@en
Gareth Gerrard
@es
Gareth Gerrard
@nl
Gareth Gerrard
@sl
P106
P1153
8737995700
P21
P31
P496
0000-0002-4614-227X